TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure

Background: Tyrosine kinase inhibitors (TKI) in combination with programmed cell death-1 (PD-1) inhibitors become the potential treatment modality for patients undergoing unresectable hepatocellular carcinoma (uHCC) in the first-line setting. However, the efficacy and safety of this combination regi...

Full description

Bibliographic Details
Main Authors: Jin Lei, Bowen Chen, Meiru Song, Linzhi Zhang, Xinfeng Zhang, Xiaoqiang Gao, Yinyin Li, Yinying Lu, Shi Zuo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
hepatocellular carcinoma
tyrosine kinase inhibitor (EGFR-TKI)
programmed death-1 inhibitor
second-line
sorafenib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1026337/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1026337/full

Similar Items